Modern approaches to age-old questions about thyroid tumors

Thyroid

Volumn 15, Issue 6, 2005, Pages 575-582

  Diehl, Susanne ^a   Umbricht, Christopher B ^a   Dackiw, Alan P B ^a   Zeiger, Martha A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; VATALANIB;

CANCER RECURRENCE; CELL DIFFERENTIATION; DISEASE MARKER; DNA FINGERPRINTING; GENE EXPRESSION REGULATION; GENE TECHNOLOGY; HUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURGICAL TECHNIQUE; THYROID CANCER; THYROID NODULE; THYROID TUMOR;

HUMANS; PROGNOSIS; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 22244452669     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2005.15.575     Document Type: Review

References (46)

1. Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA, Fahey TJ 3rd 2003 Classification of follicular thyroid tumors by molecular signature: Results of gene profiling. Clin Cancer Res 9:1792-1800.
2. Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK 2004 Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 64:2898-2903.
3. Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RM, Peterson B, Shoemaker J, Riggins GJ 2004 A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 113:1234-1242.
4. Finley DJ, Arora N, Zhu B, Gallagher L, Fahey TJ, 3rd 2004 Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89:3214-3223.
5. Schulze A, Downward J 2001 Navigating gene expression using microarrays - A technology review. Nat Cell Biol 3:E190-195.
6. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW 1995 Serial analysis of gene expression. Science 270:484-487.
7. Yamamoto M, Wakatsuki T, Hada A, Ryo A 2001 Use of serial analysis of gene expression (SAGE) technology. J Immunol Methods 250:45-66.
8. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA 2002 Clinical proteomics: Translating benchside promise into bedside reality. Nat Rev Drug Discov 1:683-695.
9. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM 1989 Electrospray ionization for mass spectrometry of large biomolecules. Science 246:64-71.
10. Koy C, Mikkat S, Raptakis E, Sutton C, Resch M, Tanaka K, Glocher MO 2003 Matrix-assisted laser desorption/ionization-quadrupole ion trap-time of flight mass spectrometry sequencing resolves structures of unidentified peptides obtained by in-gel tryptic digestion of haptoglobin derivatives from human plasma proteomes. Proteomics 3:851-858.
11. Karas M, Hillenkamp F 1988 Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem 60:2299-2301.
12. Yip TT, Lomas L 2002 SELDI ProteinChip array in oncoproteomic research. Technol Cancer Res Treat 1:273-280.
13. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbuk M, Mesirov JP, Coller H. Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES 1999 Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286:531-537.
14. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ 2002 MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30:41-47.
15. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteiler M, Kallioniemi OP, Wilfond B, Borg A, Trent J 2001 Gene-expression profiles in hereditary breast cancer N Engl J Med 344:539-548.
16. Hedenfalk I, Ringner M, Ben-Dor A, Yakhini Z, Chen Y, Chebil G, Ach R, Loman N, Olsson H, Meltzer P, Borg A, Trent J 2003 Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 100:2532-2537.
17. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastic T, Eisen MB, Van de Rijn M, Jeffrey SS, Thorsen T, Quist M, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874.
18. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Loaning PE, Brown PO, Borresen-Dale AL, Botstein D 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423.
19. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA 2002 Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577.
20. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchik A, Van Haaften-Day C, Hacker NF, de Bruijii HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW 2004 Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64:5882-5890.
21. Segev DL, Clark DP, Zeiger MA, Umbricht C 2003 Beyond the suspicious thyroid fine needle aspirate. A review. Acta Cytol 47:709-722.
22. Fagin JA 2002 Perspective: Lessons learned from molecular genetic studies of thyroid cancer-insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology 143:2025-2028.
23. Ringel MD 2000 Molecular diagnostic tests in the diagnosis and management of thyroid carcinoma. Rev Endocr Metab Disord 1:173-181.
24. Trovato M, Villari D, Bartolone L, Spinella S, Simone A, Violi MA, Trimarchi F, Batdo D, Benvenga S 1998 Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. Thyroid 8:125-131.
25. Chen KT, Lin JD, Chao TC, Hsuch C, Chang CA, Wing HF, Chan EC 2001 Identifying differentially expressed genes associated with metastasis of follicular thyroid cancer by cDNA expression array Thyroid 11:41-46.
26. von Wasielewski R, Seth S, Franklin J, Fischer R, Hubner K, Hansmann ML, Diehl V, Georgii A 2000 Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 95:1207-1213.
27. Ying H, Suzuki H, Furumoto H, Walker R, Meltzer P, Willingham MC, Cheng SY 2003 Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis 24:1467-1479.
28. Huang SH, Wu JC, Chang KJ, Liaw KY, Wang SM 1999 Expression of the cadherin-catenin complex in well-differentiated human thyroid neoplastic tissue. Thyroid 9:1095-1103.
29. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R, Dohner H, Pollack JR 2004 Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350:1605-1616.
30. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM 2000 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511.
31. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR 2002 Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning Nat Med 8:68-74.
32. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley, PS, Bernards R, Friend SH 2002 Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536.
33. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D Molecular portraits of human breast tumours. Nature 406:747-752.
34. Brachat A, Pierrat B, Xynos A, Brecht K, Simonen M, Brungger A, Heim J 2002 A microarray-based, integrated approach to identify novel regulators of cancer drug response and apoptosis. Oncogene 21:8361-8371.
35. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutrierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P 2003 Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369.
36. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, Liu ET 2002 Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4:R3.
37. Blume-Jensen P, Hunter T 2001 Oncogenic kinase signalling. Nature 411:355-365.
38. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M 2001 Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042.
39. Sawyers CL 2003 Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 17:2998-3010.
40. Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, Mitsutake N, Kanda S, Kurebayashi J, Yamashita S 2003 The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88:1889-1896.
41. Dziba JM, Ain KB 2004 Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. J Clin Endocrinol Metab 89:2127-2135.
42. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C 2004 Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: An animal study. Endocrinology 145:1031-1038.
43. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky P 2003 BRAF mutation in papillary thyroid carcinoma J Natl Cancer Inst 95:625-627.
44. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes, J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417:949-954.
45. Tuveson DA, Weber BL, Herlyn M 2003 BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4:95-98.
46. Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Holzer D, Koepffler HP, Ottmanrv OG 2002 Relation between resistance of Philadelphia-chromosome- positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: A gene-expression study. Lancet 359:481-486.